MicroRNA-488 serves as a diagnostic marker for atherosclerosis and regulates the biological behavior of vascular smooth muscle cells

Figures & data

Table 1. Clinical data of the study population

Features	Healthy controls (n = 60)	AS patients (n = 125)	P value
Age (years)	49.62 ± 4.73	50.71 ± 6.06	0.182
Gender (male/female)	34/36	64/61	0.488
BMI (kg/m^2)	22.87 ± 3.71	23.24 ± 2.68	0.490
Total cholesterol (mg/dl)	167.78 ± 33.99	171.97 ± 23.08	0.390
HDL-C (mg/dl)	51.49 ± 10.01	52.95 ± 8.07	0.326
LDL-C (mg/dl)	118.46 ± 20.41	120.90 ± 16.27	0.419
Triglyceride (mg/dl)	169.93 ± 31.54	177.85 ± 20.97	0.081
Heart rate (beats/min)	78.36 ± 18.68	81.91 ± 15.37	0.173
SBP (mm Hg)	131.62 ± 14.99	129.54 ± 10.66	0.339
DBP (mm Hg)	78.68 ± 5.26	78.23 ± 8.96	0.669
CRP (mg/l)	6.21 ± 1.60	17.16 ± 2.47	0.000

Figure 1. The expression level of serum miR-488 in AS patients and the correlation study between miR-488 expression and CIMT. (a) The expression level of serum miR-488 was upregulated in AS patients compared with healthy controls. ***P < 0.001. (b) Serum miR-488 level was positively correlated with CIMT in patients in AS patients (r = 0.706, ***P < 0.001)

Figure 2. A ROC curve was established to assess the specificity and sensitivity of miR-488 to differentiate between AS and healthy controls, the miR-488 has quite well performance with an AUC score of 0.892

Figure 3. Effects of miR-488 expression levels on cell proliferation and migration abilities in VSMCs cells. (a) qRT-PCR was used to analyze the expression level of miR-488 after transient transfection with miR-488 mimic/inhibitor (or mimic/inhibitor NC). (b) The CCK-8 assay was performed to study cell proliferation. (c) Cell migration abilities were assessed with Transwell assay. ***P < 0.001, *P < 0.05

Data availability statement

Corresponding authors may provide data and materials.